Eli Lilly and Co received the green light to distribute bamlanivimab for the treatment of patients 12 years and older with mild to moderate COVID-19 infections Friday, according to the Health Canada website.
Treatment is for people who are at risk of developing severe COVID-19 symptoms or being hospitalized – not for those who are already in the hospital or need oxygen.
According to CTV News, Lilly expects to manufacture up to a million cans for global use by the end of 2020.
Bamlanivimab is the first monoclonal antibody approved for the treatment of coronavirus and has been approved for emergency use by the Food and Drug Administration in the United States. S.. . beginning of November.
According to the publication, bamlanivimab is said to block virus attachment and entry into human cells to neutralize the virus and potentially treat COVID-19.
Lilly scientists developed the treatment in less than three months after AbCellera discovered the antibody in a blood sample from one of the first U’s. S.. . Patients to recover from the virus
1640 Ouellette Avenue
Studio / Contest Lines
newscentre @ am800cklw. com
299 Queen Street West
iHeartRadio Terms and Conditions
Political Advertisement Register
Eli Lilly and Company, Antibodies, Monoclonal Antibody Therapy, Emergency Approval, Health Canada
World News – CA – Emergency COVID-19 Antibody Treatment Approved in Canada
Donnez votre point de vue et aboonez-vous!
Votre point de vue compte, donnez votre avis
[maxbutton id= »1″]